Skip to main content

Lymphoma

FDA Oncology Update, Lymphoma

FDA Approved Breyanzi, Novel CAR T-Cell Therapy, for Large B-Cell Lymphoma

HOPA Abstracts, Clinical Trials, Leukemia, Lymphoma

Results from informCLL, a Prospective Observational Registry: Prognostic Biomarker Testing, Treatment Patterns, and Dosing in 1461 Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

FDA Oncology Update, Lymphoma

Xalkori Approved for Anaplastic Large-Cell Lymphoma and ALK Mutation in Young Patients

Meeting Highlights

ASH Highlights, CAR T-Cell Therapy, Lymphoma

ZUMA-12: Axicabtagene Ciloleucel Shows Substantial Benefit in High-Risk Large B-Cell Lymphoma

Meeting Highlights

ASH Highlights, Clinical Trials, Lymphoma

Step-Up Glofitamab Dosing Induces High Response Rates in Relapsed or Refractory Non-Hodgkin Lymphoma

FDA Oncology Update, Lymphoma

Keytruda Approved for Relapsed or Refractory Classical Hodgkin Lymphoma

Meeting Highlights

ASH Highlights, CAR T-Cell Therapy, Lymphoma

Mosunetuzumab, a Dual-Targeted Antibody, Shows Complete Remissions in Relapsed/Refractory NHL After CAR T-Cell Therapy

Meeting Highlights

ASH Highlights, Lymphoma, Novel Pharmaceuticals

Tazemetostat, First-in-Class EZH2 Inhibitor, Shows Impressive Activity in Relapsed or Refractory Follicular Lymphoma

Meeting Highlights

ASH Highlights, Immunotherapy, Lymphoma

Nivolumab Monotherapy as Bridge to Transplant in Patients with Relapsed or Refractory Hodgkin Lymphoma

Leukemia, Lung Cancer, Lymphoma, FDA Oncology Update

November 25, 2019 – Oncology News & Updates

1
2
3

Page 2 of 3
Results 11 - 20 of 28